PP_1170x120_10-25-21

Teva Canada

Teva Canadal launches bioequivalent generic version of [Pr]Gilenya, [Pr]Teva-Fingolimod capsules

Teva Canadal launches bioequivalent generic version of [Pr]Gilenya, [Pr]Teva-Fingolimod capsules

TORONTO —  Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced the launch of PrTeva-Fingolimod 0.5 mg capsules, a Health Canada approved, bioequivalent generic version of PrGilenya (fingolimod hydrochloride) in Canada. PrTeva-Fingolimod (fingolimod hydrochloride) is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations

Adheris Health